Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.
The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.
AYTU BioPharma, Inc. (AYTU) is a CNS-focused pharmaceutical company that has repositioned around commercial-stage prescription products, led by EXXUA, an FDA-approved extended-release antidepressant for adult major depressive disorder. The company exited its Consumer Health business in fiscal 2025 and now operates as a single commercial segment.
In fiscal 2026 AYTU generated $57.6 million in net revenue, including $6.6 million from the successful launch of EXXUA, while its ADHD portfolio produced $45.8 million and its pediatric product Karbinal ER $5.1 million amid reduced promotion. The company reported a $14.3 million net loss and an accumulated deficit of $347.8 million, but is prioritizing operational efficiencies and higher-margin products to pursue positive operating cash flow.
AYTU’s capital structure includes a term loan and revolving credit facility under the Eclipse Agreement, both maturing in 2029, and a June 2025 equity raise that delivered $14.8 million in net proceeds to support EXXUA commercialization. Key risks include double‑digit revenue declines in ADHD and pediatric portfolios, high customer concentration, a Paragraph IV challenge to Adzenys, extensive regulatory and compliance obligations, and the possibility of Nasdaq delisting if listing standards are not maintained.
Aytu BioPharma, Inc. (AYTU) reported fiscal 2026 Q4 and full-year results highlighting early EXXUA traction and mixed legacy portfolio trends. Q4 2026 net revenue was $16.1 million, up 6.4% from $15.1 million, with EXXUA contributing $3.9 million and the ADHD Portfolio $10.4 million.
Q4 net loss was approximately break-even at less than $0.1 million, versus a $19.8 million loss a year earlier, and Adjusted EBITDA was $0.5 million. For fiscal 2026, net revenue was $57.6 million versus $66.4 million, and net loss was $14.3 million versus $13.6 million. Full-year Adjusted EBITDA declined to -$3.7 million from $9.2 million as the company increased EXXUA commercialization investments.
EXXUA generated $6.6 million in fiscal 2026 net revenue, including 3,323 prescriptions in Q4, up about 138% from 1,398 in Q3. As of June 30, 2026, cash and equivalents were $26.3 million and stockholders’ equity was $35.3 million, aided by reclassification that reduced derivative warrant liabilities to $1.2 million.
Aytu BioPharma, Inc. has a significant shareholder, Laurence W. Lytton, and the Lytton-Kambara Foundation jointly reporting beneficial ownership of Aytu common stock. Each reports 545,946 shares beneficially owned, representing 4.99% of the common stock, based on 10,733,208 shares outstanding as of April 30, 2026. All voting and dispositive powers are reported as shared, with no sole power held by either reporting person. The holdings include existing common shares and warrants to purchase additional shares, all subject to a 4.99% beneficial ownership limitation. The parties also provide a joint filing agreement covering their Schedule 13D or 13G submissions.
Disbrow Joshua R. reported acquisition or exercise transactions in this Form 4 filing.
Joshua R. Disbrow, chief executive officer and director of Aytu Biopharma, received a grant of 30,000 shares of restricted common stock on July 28, 2026 at $0.00 per share. One-third vests on July 28, 2027, with the rest vesting in eight equal quarterly installments beginning October 28, 2027. After this award, he directly holds 237,203 common shares.
PYSZCZYMUKA GREG reported acquisition or exercise transactions in this Form 4 filing.
Aytu BioPharma Chief Commercial Officer Greg Pyszczymuka received a grant of 20,000 shares of restricted common stock on July 28, 2026 at $0.0000 per share. One-third vests on July 28, 2027, with the remainder in eight quarterly installments from October 28, 2027. Following this award he directly holds 56,102 shares.
Disbrow Jarrett reported acquisition or exercise transactions in this Form 4 filing.
Jarrett Disbrow, Chief Business Officer of AYTU Biopharma, reported a grant of 15,000 shares of common stock as restricted stock. The award increases his direct holdings to 76,568 shares and vests over time starting July 28, 2027 in quarterly installments.
AYTU BioPharma’s Chief Financial Officer, Ryan J. Selhorn, received a grant of 25,000 shares of restricted common stock on July 28, 2026. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments beginning October 28, 2027. Following this award, he directly holds 74,743 shares of common stock. The award is a grant/award acquisition rather than a market purchase and was not made under a Rule 10b5-1 trading plan.
LIU VIVIAN H reported acquisition or exercise transactions in this Form 4 filing.
Aytu Biopharma director Vivian H. Liu received a grant of 10,000 shares of restricted common stock on July 28, 2026. The restricted stock vests on July 28, 2027. Following this grant, Liu directly holds 29,825 shares of Aytu Biopharma common stock.
JAIN ABHINAV reported acquisition or exercise transactions in this Form 4 filing.
AYTU Biopharma reported that director Abhinav Jain received a grant of 10,000 shares of Common Stock as restricted stock on July 28, 2026, at a stated price of $0.0000 per share. These shares vest on July 28, 2027. After this award, Jain directly holds 29,500 shares of AYTU common stock.
DOCKERY CARL reported acquisition or exercise transactions in this Form 4 filing.
Aytu BioPharma director Carl Dockery received a grant of 10,000 shares of restricted common stock on July 28, 2026. The shares vest on July 28, 2027, and his directly held position increased to 31,152 shares after this compensation-related award.